



What do we know about the ocular adverse effects associated with intravenous bisphosphonates?

İntravenöz bifosfonatların göze yan etkileri hakkında ne biliyoruz?

O. Şahap Atik, M.D.

Department of Orthopedics and Traumatology, Medical Faculty of Gazi University, Ankara, Turkey

There are reports indicating some bisphosphonates cause several types of ocular inflammation and may result in serious ocular damage.^[1,5]

Several cases of severe ocular problems have occurred one day after the administration of intravenous zoledronic acid.^[6-8] The mechanism is not yet clear, but the patients are treated with high-dose oral or topical steroids and ocular signs and symptoms eventually resolve.

Physicians prescribing these drugs should be aware of these side effects which are potentially devastating if not recognized and treated appropriately.^[6]

All patients receiving bisphosphonates who develop ocular signs and symptoms should be referred promptly to an ophthalmologist.

REFERENCES

1. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. *N Engl J Med* 2003;348:1187-8.
2. Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. *Clin Oncol (R Coll Radiol)* 2006; 18:545-6.
3. Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. *N Engl J Med* 2008;359:1410-1.
4. Mbekeani JN, Slamovits TL. Bisphosphonate-induced orbital inflammation. *J Neuroophthalmol* 2010;30:205-6.
5. Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate-induced orbital inflammation. *J Neuroophthalmol* 2010;30:94-5.
6. Benderson D, Karakunnel J, Kathuria S, Badros A. Scleritis complicating zoledronic acid infusion. *Clin Lymphoma Myeloma* 2006;7:145-7.
7. Colucci A, Modorati G, Miserocchi E, Di Matteo F, Rama P. Anterior uveitis complicating zoledronic acid infusion. *Ocul Immunol Inflamm* 2009;17:267-8.
8. Procionoy F, Procionoy E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. *Osteoporos Int* 2010;21:1057-8.